Event-free survival in patients with early triple-negative breast cancer receiving platinum-free, de-escalated anti-PD-1 neoadjuvant therapy: an updated analysis of the NeoTENNIS trial
Event-free survival in patients with early triple-negative breast cancer receiving platinum-free, de-escalated anti-PD-1 neoadjuvant therapy: an updated analysis of the NeoTENNIS trial. // Cancer Letters. – URL: https://www.sciencedirect.com/science/article/pii/S0304383526007172?dgcid=rss_sd_all
Event-free survival in patients with early triple-negative breast cancer receiving platinum-free, de-escalated anti-PD-1 neoadjuvant therapy: an updated analysis of the NeoTENNIS trial. Cancer Letters. https://www.sciencedirect.com/science/article/pii/S0304383526007172?dgcid=rss_sd_all
“Event-free survival in patients with early triple-negative breast cancer receiving platinum-free, de-escalated anti-PD-1 neoadjuvant therapy: an updated analysis of the NeoTENNIS trial.” Cancer Letters.
@article{article39524,
title = {Event-free survival in patients with early triple-negative breast cancer receiving platinum-free, de-escalated anti-PD-1 neoadjuvant therapy: an updated analysis of the NeoTENNIS trial},
journal = {Cancer Letters},
url = {https://www.sciencedirect.com/science/article/pii/S0304383526007172?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment